Home › NDC Lookup › RxCUI directory › RxCUI 2729794

Cariprazine 0.5 MG Oral Capsule [Vraylar] — RxCUI 2729794

RxNorm drug concept · Semantic branded drug
RxCUI 2729794 Semantic branded drug · SBD ● Current RxNorm concept 7 FDA products 13 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2729794
Official nameCariprazine 0.5 MG Oral Capsule [Vraylar]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asVraylar 0.5 MG Oral Capsule
FDA products mapped7
Package NDCs mapped13
Reported Medicaid activity (SDUD)1,076,596 prescriptions · 51 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Cariprazine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Vraylar is used for a few different conditions depending on your age. For adults, it can treat schizophrenia, manic or mixed episodes of bipolar I disorder, the depressive episodes...
  • This one takes some patience. Vraylar and its active breakdown products build up in your system slowly — it can take a week or two to start noticing changes, and full effects may n...
  • How long does it take for Vraylar to start working?
  • The most common things people notice are a feeling of restlessness or the urge to keep moving (called akathisia), stiffness or tremor in the muscles, nausea, constipation, or fatig...
📖 Read our full Cariprazine guide →

🕸️ Concept Web — How Cariprazine 0.5 MG Oral Capsule [Vraylar] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Cariprazine 0.5 MG Oral Capsule [Vraylar] RxCUI 2729794

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Cariprazine 1667655
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Vraylar 1667661
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Cariprazine Oral Capsule 1667659
    • Cariprazine Oral Product 1667657
    • Cariprazine Pill 1667658
    • Cariprazine Oral Capsule [Vraylar] 1667663
    • Vraylar Oral Product 1667664
    • Vraylar Pill 1667665
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Cariprazine 0.5 MG Oral Capsule SCD · 2729792
  • Cariprazine 0.5 MG SCDC · 2729791
  • Cariprazine Oral Capsule SCDF · 1667659
  • Cariprazine Oral Product SCDG · 1667657
  • Cariprazine Pill SCDG · 1667658

Brand-Name Concepts

  • Cariprazine 0.5 MG [Vraylar] SBDC · 2729793
  • Cariprazine Oral Capsule [Vraylar] SBDF · 1667663
  • Vraylar Oral Product SBDG · 1667664
  • Vraylar Pill SBDG · 1667665
  • Vraylar BN · 1667661

📦 FDA Products & Package NDCs

7 products · 13 package NDCs
13 package NDCs map to RxCUI 2729794 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
61874-0115-07 7 CAPSULE, GELATIN COATED in 1 BLISTER PACK (61874-115-07) Vraylar Allergan, Inc. 2016-03-01
61874-0115-17 1 BLISTER PACK in 1 CARTON (61874-115-17) / 7 CAPSULE, GELA... Vraylar Allergan, Inc. 2016-03-01
61874-0115-20 2 BLISTER PACK in 1 CARTON (61874-115-20) / 10 CAPSULE, GEL... Vraylar Allergan, Inc. 2016-03-01
61874-0115-30 30 CAPSULE, GELATIN COATED in 1 BOTTLE (61874-115-30) Vraylar Allergan, Inc. 2016-03-01
61874-0130-07 7 CAPSULE, GELATIN COATED in 1 BLISTER PACK (61874-130-07) Vraylar Allergan, Inc. 2016-03-01
61874-0130-20 2 BLISTER PACK in 1 CARTON (61874-130-20) / 10 CAPSULE, GEL... Vraylar Allergan, Inc. 2016-03-01
61874-0130-30 30 CAPSULE, GELATIN COATED in 1 BOTTLE (61874-130-30) Vraylar Allergan, Inc. 2016-03-01
61874-0145-07 7 CAPSULE, GELATIN COATED in 1 BLISTER PACK (61874-145-07) Vraylar Allergan, Inc. 2016-03-01
61874-0145-30 30 CAPSULE, GELATIN COATED in 1 BOTTLE (61874-145-30) Vraylar Allergan, Inc. 2016-03-01
61874-0160-07 7 CAPSULE, GELATIN COATED in 1 BLISTER PACK (61874-160-07) Vraylar Allergan, Inc. 2016-03-01
61874-0160-30 30 CAPSULE, GELATIN COATED in 1 BOTTLE (61874-160-30) Vraylar Allergan, Inc. 2016-03-01
61874-0250-30 30 CAPSULE, GELATIN COATED in 1 BOTTLE (61874-250-30) Vraylar Allergan, Inc. 2025-12-18
61874-0275-30 30 CAPSULE, GELATIN COATED in 1 BOTTLE (61874-275-30) Vraylar Allergan, Inc. 2025-12-18
Observed labelers: Allergan, Inc. (13) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.